We are live on ! Find out more
IPCI

Intellipharmaceuticals International Inc.
IPCI

Delisted

IPCI was delisted on the 20th of March, 2019.

24 hedge funds and large institutions have $6.31M invested in Intellipharmaceuticals International Inc. in 2018 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more capital invested

Capital invested by funds: $3.16M → $6.31M (+$3.15M)

14% less funds holding

Funds holding: 2824 (-4)

43% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 7

50% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 6

65% less call options, than puts

Call options by funds: $6K | Put options by funds: $17K

Holders
24
Holders Change
-4
Holders Change %
-14.29%
% of All Funds
0.55%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
4
Reduced
7
Closed
6
Calls
$6K
Puts
$17K
Net Calls
-$11K
Net Calls Change
+$49K
Name Holding Trade Value Shares
Change
Change in
Stake
AC
1
Armistice Capital
New York
$4.89M +$4.82M +666,400 +344%
AFM
2
Anson Funds Management
Texas
$1.21M +$1.54M +212,872 New
VF
3
Virtu Financial
New York
$35K +$24.6K +3,399 +123%
ATC
4
Argent Trust Co
Tennessee
$34K
Morgan Stanley
5
Morgan Stanley
New York
$31K -$7.56K -1,046 -16%
Bank of Montreal
6
Bank of Montreal
Ontario, Canada
$18K +$181 +25 +0.8%
AG
7
Advisor Group
Arizona
$17K -$6.62K -916 -23%
BAM
8
Belpointe Asset Management
Nevada
$17K -$759 -105 -3%
VAM
9
Verity Asset Management
North Carolina
$17K
Royal Bank of Canada
10
Royal Bank of Canada
Ontario, Canada
$9K -$231 -32 -2%
WP
11
WealthShield Partners
North Carolina
$9K
Geode Capital Management
12
Geode Capital Management
Massachusetts
$7K
Barclays
13
Barclays
United Kingdom
$7K +$9.03K +1,250 New
FFA
14
First Foundation Advisors
California
$6K -$346K -47,917 -98%
Group One Trading
15
Group One Trading
Illinois
$4K
FANJ
16
Financial Architects (New Jersey)
New Jersey
$1K
FMA
17
FNY Managed Accounts
New York
$1K +$1.52K +210 New
FDCDDQ
18
Federation des caisses Desjardins du Quebec
Quebec, Canada
$78 -$14 -2 -13%
SM
19
Sabby Management
Florida
-$867K -108,364 Closed
Susquehanna International Group
20
Susquehanna International Group
Pennsylvania
-$37K -4,614 Closed
Citadel Advisors
21
Citadel Advisors
Florida
-$8.14K -1,126 Closed
UBS Group
22
UBS Group
Switzerland
-$7K -862 Closed
Deutsche Bank
23
Deutsche Bank
Germany
-$5K -681 Closed
TDC
24
Thompson Davis & Co
Virginia
-$2K -250 Closed
TRCT
25
Tower Research Capital (TRC)
New York
-$289 -40 -80%

IPCI Hedge Fund Activity: Q1 2018 in Review

24 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Intellipharmaceuticals International Inc. (IPCI) for Q1 2018, worth a combined $6.31M — up 100% from $3.16M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of IPCI and 3 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 4 added.

The largest buyer was Armistice Capital, adding an estimated $4.82M. The largest seller was Sabby Management, exiting entirely with an estimated $867K sold.

  • 24 institutional investors held Intellipharmaceuticals International Inc. (IPCI) as of Q1 2018, down from 28 in Q4 2017.
  • Funds reported $6.31M of Intellipharmaceuticals International Inc. stock for Q1 2018, up 100% quarter-over-quarter.
  • 3 funds opened new Intellipharmaceuticals International Inc. positions in Q1 2018 and 6 closed out, a net change of -3 holders.
  • The largest Intellipharmaceuticals International Inc. buyer in Q1 2018 was Armistice Capital, an estimated $4.82M added.
  • The largest Intellipharmaceuticals International Inc. seller in Q1 2018 was Sabby Management, an estimated $867K sold.

Based on aggregated 13F filings for Q1 2018.